Drugs / Marvelon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT00565240 | Nov 2007 → Sep 2009 | — | University of Saskatchewan | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT01256619 Comparator | Sep 2010 | premenstrual tension | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT03197077 Background | Nov 2017 → Dec 2022 | female infertility, polycystic ovary syndrome | University Hospital Brussels | Completed | No outcome recorded |
| Phase 4 | NCT03953716 Comparator | Jun 2019 → Jun 2020 | primary dysmenorrhea | Peking Union Medical College Hospital | Unknown | Missed primary |
| Phase 4 | NCT00778999 Comparator | Oct 2006 → Jul 2008 | infertility disorder | Organon and Co | Completed | No outcome recorded |
| — | NCT01298128 Comparator | Feb 2006 → Mar 2010 | infertility disorder | University of Toronto | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Marvelon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01256619 ↗ |
| Modality | Small molecule | — CHEMBL1697756 ↗ |
| Route | Oral | “oral contraceptive” NCT00565240 ↗ |